Australia fulfils HIV/AIDS funding commitments to Asia-Pacific:
This article was originally published in Clinica
Executive Summary
Australia has committed almost Aus$400m (US$325m) to its Asia-Pacific HIV/AIDS programmes. Last year, Aus$600m was allocated, completing Australia's original Aus$1bn pledge to this region. This year, Indonesia will receive Aus$86m to improve its HIV/AIDS services, as part of a partnership between the two countries. The funds are to be distributed by 2010, through Australia's foreign aid agency AusAID. Special focus will be on Papua New Guinea, where there has been a significant increase in the incidence of HIV/AIDS during the past 10 years (see Clinica No 1246, p 10).
You may also be interested in...
How Ochre Bio Bagged Boehringer For Its RNA-Based Regenerative MASH Therapies
UK-based Ochre Bio has signed its first major deal with Boehringer Ingelheim. Scrip talked to its co-founder and CEO, Jack O’Meara, about its human tissue-based drug discovery platform, its resulting RNA platform for liver disease and how the fledgling drug company's early work mirrored that seen in diagnostics.
IGI Bets On Trispecific Antibody To Make Inroads Into Big Pharma Myeloma Turf
Ichnos Glenmark Innovation’s president and CEO talks to Scrip about the promising activity profile of the alliance’s early stage trispecific antibody versus Janssen’s teclistamab and also maintains that the setback for Gilead’s magrolimab hasn’t eclipsed prospects for its bispecific antibody.
UK Medtech Strategy Sets Out Schedule Of Milestones To FY 2026
Fourteen months on from the release of its inaugural medtech strategy, the UK MedTech Directorate has laid firm foundations and reports progress on initiatives aimed at improving technology adoption. A schedule of ambitious future timelines has also been published.